In the Media
Are you looking for the latest media coverage of the BioMed X Institute, its research projects and people behind the innovation model? Here you will find the latest clippings – hot off the press!
Merck Healthcare Business, BioMed X Begin New Research Project in Oncology
Medical Dialogues
Germany. BioMed X, a German independent research institute, has announced the start of its new research project titled ‘Extrachromosomal DNA in Cancer’ (EDC) in collaboration with Healthcare Business of Merck KGaA, Darmstadt, Germany.
BioMed X Institute Enters New Collaboration with Merck
The Pharma Letter
German independent research institute BioMed X has announced the start of its new research project âExtrachromosomal DNA in Cancerâ (EDC) in collaboration with the Healthcare Business of Germanyâs Merck KGaA, Darmstadt. The main objective of this research group is to develop an atlas of extrachromosomal DNA (ecDNA) in human cancer tissues and thereby trace back the mechanisms of ecDNA formation…
BioMed X Institute and Merck Start New Oncology Research Project
Labiotech.eu
BioMed X, a German independent research institute, has started a new research project âExtrachromosomal DNA in Cancerâ (EDC) in collaboration with the Healthcare Business of Merck KGaA, Darmstadt, Germany. The main objective of this research group is to develop an atlas of extrachromosomal DNA (ecDNA) in human cancer tissues and trace back the mechanisms of ecDNA formation and function.
AION Labs, In Continued Partnership with BioMed X, Launches Fourth Global Call for Application: Prediction of Clinical Trial Outcome in Cancer Patient Populations
Mobile Health Times
AION Labs, Israel-based alliance of AstraZeneca, Merck, Pfizer, Teva, Israel Biotech Fund and Amazon Web Services (AWS), seeks global research talent for new startup focused on: âPrediction of Clinical Trial Outcome in Biomarker-Stratified Cancer Patient Populationsâ.
Global Call for Scientists and Inventors to Form New Startup
Labiotech.eu
AION Labs and German independent research institute BioMed X, announced today (June 29) the launch of the fourth global call for application to identify biomedical scientists and inventors to form a new startup in Israel. This fourth startup will focus on the development of an AI platform that optimizes the patient population for phase 3 clinical trial oncology studies.
BioMed X Ukraine Refugee Funding Program Included in the Science for Ukraine Database
#ScienceForUkraine
The BioMed X Institute, an independent research institute located in Heidelberg, Germany, is offering PhD positions in the field of Life Sciences (including pharmacology, bio-organic chemistry and physics) to early-career scientists from Ukraine.
Artificial Intelligence âBoot Campâ Aims to Accelerate Drug Discovery
Health Policy Watch
Together with its German partner BioMed X, AION Labs hosted 15 teams of computational biologists, AI researchers and biomedical scientists for a âboot campâ that aims to speed up the drug discovery process and lower costs â harnessing AI technologies in novel ways.
Joint Research Project to Examine Regulatory T Cell Dysfunction in Autoimmunity and Inflammaging
LABMATE Online
A German independent research institute, BioMed X, announces today the start of its new research project âRegulatory T Cell Dysfunction in Autoimmunity and Inflammagingâ (TDA) in collaboration with Merck KGaA, Darmstadt, Germany.
Israel’s AION Labs Lanches Third Call For Proposals To Develop Antibody Therapies
nocamels
Israeli-headquartered, AION Labs, and German independent research institute, BioMed X, this week announced their third global call for biomedical scientists and interested investors to apply for a new AION Labs startup in Rehovot focused on âAI-enabled design and optimization of antibodies for targeted therapiesâ.
AION Labs, Powered by BioMed X, Launches Third Global Call for Application: Artificial Intelligence for Design and Optimization of Antibodies for Targeted Therapies
AITHORITY
AION Labs, a first-of-its-kind innovation lab spearheading the adoption of AI technologies and computational science to solve therapeutic challenges, and German independent research institute BioMed X, announced the launch of the third global call for application to identify biomedical scientists and inventors to form a new startup at AION Labsâ headquarters in Rehovot, Israel.
Unravelling New Disease Biology at the Interface Between Academia and the Pharma Industry
European Biopharmaceutical Review
Making the case for focusing investments on drug discovery over development. What are some of the innovation models that have thrived, and what are the key success factors in those models?
Ein Pionier der translationalen biomedizinischen Forschung â Das BioMed X Institut in Heidelberg
BioDeutschland Jahrbuch 2021/2022
Meilensteine in der Medizin sind meist das Ergebnis von in- novativer, kreativer und risikoreicher Forschung. Eines der fĂŒh- renden Zentren in Deutschland an der Schnittstelle zwischen akademischer und industrieller biomedizinischer Forschung ist das BioMed X Institut in Heidelberg.